Breaks Categories: News

TuesdayOct 26, 2021 1:54 pm

PsychedelicNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) Enters Agreement with Aragen Life Sciences to Produce Innovative Drug Candidate

Clearmind Medicine (CSE: CMND) (FSE: CWY0), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announced its entry into a development and supply agreement with Aragen Life Sciences Pvt. Ltd for the production of its innovative molecule, 5-Methoxy-2-aminoindane (“MEAI”). Aragen is a global leader in providing discovery, development and manufacturing solutions for life sciences firms under Good Manufacturing Practices. Under the agreement, Aragen will complete a process optimization and synthesis, manufacturing and supply of MEAI to Clearmind. “Aragen is a world-class, life-sciences company with state-of-the-art manufacturing…

Continue Reading

TuesdayOct 26, 2021 1:29 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces FDA IND Authorization of Potentially Pivotal Study

Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has announced that the U.S. Food and Drug Administration (“FDA”) has authorized an Investigational New Drug (“IND”) application to proceed with the company’s sponsored feasibility study. The study focuses on using Kernel’s Flow technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. “The word psychedelic means ‘mind-manifesting,’ but what has been missing is useful ‘mind-imaging’—the ability to dynamically trace the neural correlates of human conscious experience,” said Cybin’s Chief Clinical Officer Dr. Alex Belser. “Conventional neuroimaging just isn’t dynamic enough to study the psychedelic experience…

Continue Reading

TuesdayOct 26, 2021 12:11 pm

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at Upcoming Pain Therapeutics Summit

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has announced that it will present at the 15th Annual Pain Therapeutics Summit. The event is slated to take place on Nov. 1-3, 2021, with Tryp’s presentation scheduled to begin at 11:15 a.m. Central Time / 12:15 p.m. Eastern Time on Nov. 1. Chairman and CEO Greg McKee will provide an overview of the company followed by a live question-and-answer session with emphasis on the chronic pain indications that Tryp is pursuing including fibromyalgia, phantom limb pain, and complex regional…

Continue Reading

TuesdayOct 26, 2021 12:02 pm

PsychedelicNewsBreaks – Delic Holdings Inc.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Lab Facility Enters Partnership with GT Research for Comarketing Efforts

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has inked a comarketing agreement focused on computational genetic analysis and trait optimization for cannabis and psychedelics. The agreement was signed through Delic Labs, which inked the deal with GTR Research Inc. (“GTR”). GTR is leading out in applying cutting-edge computational and biotech to cannabis and psychedelics. According to the company, Delic Labs will provide genetic analysis of psychedelic mushrooms and cannabis to producers in Canada; the analysis will include sample preparation, DNA extraction, whole-genome sequencing, computational analysis and reporting, as…

Continue Reading

ThursdayOct 21, 2021 9:52 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Clinical Hold on Planned Eating Disorder Phase 2a Study

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, reported that the U.S. Food and Drug Administration ("FDA") has placed a clinical hold on its upcoming Phase 2a study for eating disorders. According to the announcement, the FDA did not cite a reason for the hold but would provide additional information regarding the hold in the next month. Although the study is now on hold, the company noted that it still expects to move forward with plans to file an IND for its Phase 2a study in fibromyalgia; that…

Continue Reading

TuesdayOct 19, 2021 10:50 am

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces Founder of Synergy Soul to Headline at Meet Delic

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, today announced that Brittany Hoogenboom will serve as a keynote speaker at Meet Delic on Nov. 7, 2021. Hoogenboom is the owner and founder of Synergy Soul, a brand focused on personal transformation through a holistic, integrated approach to life, business and wealth. She is also a certified physical therapy assistant, reiki master and yoga instructor. “We are very excited to have Brittany’s fresh voice and approach to personal transformation at Meet Delic,” said Delic co-founder, Jackee Stang. “She has a unique way of integrating health, wellness, spirituality and…

Continue Reading

TuesdayOct 19, 2021 10:12 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Completion of 74 In-Vitro and In-Vivo Evaluations of Expanding Portfolio

Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has announced the completion of its 74th pre-clinical study as it continues to progress its proprietary psychedelic molecules into Investigational New Drug (“IND”)-enabling studies. According to the update, Cybin’s research and development team has completed 74 in-vitro and in-vivo evaluations of the company’s expanding portfolio of psychedelic compounds being designed for potential therapeutic applications for several mental health conditions. More than 50 novel compounds have been evaluated to date through collaborations with experienced contract research organizations for pharmacokinetic/pharmacodynamic profile, metabolic stability, receptor binding and safety to…

Continue Reading

FridayOct 15, 2021 10:39 am

PsychedelicNewsBreaks – IBN and PsychedelicNewsWire to Heighten Visibility, Widen Reach of Upcoming Psychedelic Capital Conference

IBN (“InvestorBrandNetwork”), a multifaceted financial news and publishing company, today announced that it will collaborate with Microdose Psychedelic Insights, a cutting-edge media company aiming to move the psychedelics industry to the forefront of modern medicine, for its upcoming event. The Psychedelic Capital Conference, set to be held in an entirely virtual format on Oct. 28, 2021, will feature the most innovative and cutting-edge companies, latest IPOs, newest opportunities and deepest insights into the global psychedelic industry. The event will serve to educate attendees on the potential uses and benefits attached to psychedelics in today’s environment, from exploring ongoing governmental policy…

Continue Reading

ThursdayOct 14, 2021 3:22 pm

PsychedelicNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) Announces Strategic Board Appointments of Distinguished Addiction Experts

Clearmind Medicine (CSE: CMND) (FSE: CWY0), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announced that professors Wim van den Brink and Gabriele Fischer have joined the company’s scientific advisory board. According to the update, van den Brink, M.D., Ph.D., is a professor of addiction psychiatry at the Academic Medical Center of the University of Amsterdam and a recognized expert in the neurobiology and pharmacological treatment of substance use disorders and behavioral addictions. Gabriele Fischer, M.D., is a professor of addiction research and treatment, medical…

Continue Reading

ThursdayOct 14, 2021 12:47 pm

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Included in AdvisorShares Psychedelics ETF

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has announced its inclusion in the AdvisorShares Psychedelics ETF (the “Fund”), currently trading under ticker symbol PSIL on the NYSE Arca exchange. According to the update, the Fund, launched in September 2021, is actively trading and focuses on companies that devote a majority of assets to psychedelic drug development. The Fund has built a portfolio including over 25 psychedelic companies. PSIL represents an exciting milestone for Tryp with the potential to bring a more diverse shareholder base and to broaden life science exposure for…

Continue Reading